Valuation : Protalix BioTherapeutics, Inc.

Market Cap 20Cr 18Cr 17Cr 15Cr 28Cr 1.96TCr 29Cr 196.17Cr 77Cr 987.35Cr 77Cr 75Cr 3.27TCr P/E 2026 *
13.4x
P/E 2027 * 46.2x
Enterprise Value 20Cr 18Cr 17Cr 15Cr 28Cr 1.96TCr 29Cr 196.17Cr 77Cr 987.35Cr 77Cr 75Cr 3.27TCr EV / Sales 2026 *
2.56x
EV / Sales 2027 * 3x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week+6.72%
Current month+7.17%
1 month+11.89%
3 months+20.38%
6 months-11.81%
Current year+41.11%
1 week 2.34
Extreme 2.34
2.65
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap.
19/12/25 Buy

Chief Executive Officer

56,000 0.0696%
18/11/25 Sell

Director

168 0.0002%
03/09/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%+6.72%+63.87%+30.26% 20Cr
-0.13%-6.44%+60.34%+112.06% 1,04700Cr
+0.85%-0.81%+51.29%+63.13% 65TCr
-1.03%-3.58%+21.43%+73.10% 45TCr
-1.46%-4.50%+37.80%+37.41% 35TCr
-0.72%-2.89%+22.32%+36.62% 29TCr
-1.19%-2.21%+1.53%+10.79% 25TCr
-1.05%-1.57%+50.30%+66.55% 23TCr
+0.08%-1.78%-17.64%-54.36% 20TCr
-2.14%-0.30%+28.95%+86.27% 18TCr
Average -0.95%-1.44%+32.02%+46.18% 36.59TCr
Weighted average by Cap. -0.46%-3.46%+38.17%+65.00%

Financials

2026 *2027 *
Net sales 7.98Cr 6.88Cr 6.45Cr 5.89Cr 11Cr 762.64Cr 11Cr 76Cr 30Cr 384.98Cr 30Cr 29Cr 1.28TCr 6.82Cr 5.88Cr 5.51Cr 5.03Cr 9.47Cr 651.76Cr 9.5Cr 65Cr 26Cr 329.01Cr 26Cr 25Cr 1.09TCr
Net income 1.54Cr 1.32Cr 1.24Cr 1.13Cr 2.14Cr 146.95Cr 2.14Cr 15Cr 5.75Cr 74Cr 5.77Cr 5.65Cr 245.96Cr 44.63L 38.46L 36.06L 32.92L 62.01L 43Cr 62.21L 4.28Cr 1.67Cr 22Cr 1.68Cr 1.64Cr 71Cr
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
28/26/28 $2.540 -2.68% 4,90,228
27/26/27 $2.610 +5.24% 12,93,530
26/26/26 $2.480 +3.33% 10,23,782
25/26/25 $2.400 -0.41% 4,97,742
24/26/24 $2.410 +1.26% 4,09,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.540USD
Average target price
11.00USD
Spread / Average Target
+333.07%

Quarterly revenue - Rate of surprise